 I think the key thing that we need to do is to incentivize the pharmaceutical industry to bring those new therapies into transplantation rather than taking them into other diseases or conditions, or in addition to taking them into studying other diseases or conditions. To do that, they need a pathway to show improvements from a regulatory standpoint with the FDA over the current therapy, also that those